Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
01:33pm, Friday, 04'th Nov 2022
Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript
02:10am, Friday, 04'th Nov 2022
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Holly Manning - Investor Relations Brian Goff - Chief Executive Officer Sar
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
11:00am, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
– U.S. PYRUKYND® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 –
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates
09:48am, Thursday, 03'rd Nov 2022
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
07:00am, Thursday, 20'th Oct 2022
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
11:13pm, Monday, 26'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined di
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
10:41am, Friday, 16'th Sep 2022 GlobeNewswire Inc.
– Agios Expects a Decision on the Marketing Authorization Application by the European Commission within 67 Days of the Adoption of the Positive CHMP Opinion – – Agios Expects a Decision on the
Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound?
03:30pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
09:29am, Friday, 02'nd Sep 2022 Benzinga
Gainers
Hempacco Co., Inc. (NASDAQ: HPCO) shares jumped 63.4% to close at $8.35 after dropping 34% on Wednesday. Hempacco's common shares began trading on the Nasdaq Tuesday. The company had planned
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
04:47pm, Thursday, 01'st Sep 2022 Benzinga
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.
Hempacco Co., Inc. (NASDAQ: HPCO) shares climbed 63% to $8.33 after dropping 34% on
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
03:14pm, Thursday, 01'st Sep 2022 Benzinga
Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash.
GigaCloud Technology Inc. (NASDAQ: GCT) sur
Agios to Participate in September Investor Conferences
11:00am, Wednesday, 24'th Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined dis
Agios to Participate in September Investor Conferences
07:00am, Wednesday, 24'th Aug 2022
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined disea
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
10:35pm, Thursday, 18'th Aug 2022 GlobeNewswire Inc.
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden –
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
10:35pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 –
